Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: Long-term follow-up

Bone Marrow Transplantation

Volumn 45, Issue 6, 2010, Pages 1119-1120

  Magni, M ^a   Di Nicola, M ^a   Carlo Stella, C ^a,b   Devizzi, L ^a   Guidetti, A ^a   Matteucci, P ^a   Gianni, A M ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; MITOXANTRONE; RITUXIMAB;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CAUSE OF DEATH; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; IN VIVO STUDY; INFECTION RATE; LETTER; LONG TERM CARE; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; WHOLE BODY RADIATION; ADULT; ADVERSE DRUG REACTION; AUTOTRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROCEDURES; SALVAGE THERAPY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

EID: 77954865842     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.294     Document Type: Letter

References (7)

1. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140-147.
2. Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26: 3614-3620.
3. Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008; 19: 1331-1335.
4. Montoto S, Canals C, Rohatiner AZS, Taghipour G, Sureda A, Schimtz N et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21: 2324-2331.
5. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized european CUP trial. J Clin Oncol 2003; 21: 3918-3927.
6. Rohatiner AZS, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow up. J Clin Oncol 2007; 25: 2554-2559.
7. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.